Sign up
Log in
George
Various-Coronavirus/AstraZeneca
FILE: Bristol, UK - 2021 (CGTN - No access Chinese mainland)
1. Various of medical worker preparing for vaccination with AstraZeneca vaccine
2. Various of elderly woman receiving AstraZeneca vaccine
FILE: London, UK - May 2, 2020 (CCTV - No access Chinese mainland)
3. UK national flag
FILE: London, UK - Jan 6, 2021 (CCTV - No access Chinese mainland)
4. "Keep Safe" sign at roadside
FILE: London, UK - Jan 12, 2021 (CCTV - No access Chinese mainland)
5. Various of pedestrians; buildings; traffic
6. Empty street
7. Tower Bridge
FILE: Madrid, Spain - Exact Date Unknown (CCTV - No access Chinese mainland)
8. Spanish national flag
Madrid, Spain - March 24, 2021 (CGTN - No access Chinese mainland)
9. Various of medical workers, residents in COVID-19 vaccination center; residents receiving vaccine
FILE: Madrid, Spain - Oct 3, 2020 (CGTN - No access Chinese mainland)
10. Various of pedestrians, people dining outdoor
FILE: Brussels, Belgium - Exact Date Unknown 2020 (CGTN - No access Chinese mainland)
11. Various of closed restaurants
12. Various of pedestrians; sign of mask wearing mandate
13. Various of medical staff dealing tubes of nucleic acid test at lab
14. Machine lifting tubs
Many countries in Europe have set the limit to age for the use of Oxford-AstraZeneca COVID-19 vaccine following occurrences of blood clot case after the jab.
In the United Kingdom, people aged 18-29 will be offered an alternative to the Oxford-AstraZeneca vaccine amid concerns over its possible link to reported rare cases of blood clots, the British government's vaccination advisory body, the Joint Committee on Vaccination and Immunization (JCVI), said Wednesday.
The announcement by the JCVI follows a review of the Oxford vaccine by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA said the side-effects of the AstraZeneca vaccine were extremely rare and the vaccine's effectiveness is proven, adding that the benefits of taking the vaccine are still very favorable for the vast majority.
However, it conceded the new approach is more finely balanced for younger people because the risk from coronavirus is much lower.
According to the MHRA, Britain has vaccinated more than 20 million people with the AstraZeneca vaccine and up to March 31, 79 cases of rare blood clots were reported, including 51 women and 28 men aged 18-79.
Also, on Wednesday, the European Medicines Agency (EMA) confirmed that the occurrence of blood clots with low blood platelets are strongly associated with the administration of AstraZeneca vaccine but should be still listed as a very rare side-effect.
In its latest assessment, EMA experts told the media that the reported combination of blood clots and low blood platelets is very rare, and the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.
EMA's Pharmacovigilance Risk Assessment Committee made the conclusion after carrying out an in-depth review of the more than 80 cases reported in the European Union (EU) database.
Following the EMA’s assessment, Spain has limited the use of AstraZeneca vaccine on Wednesday. The country announced to ban the use of the very vaccine for people under 60 and only to inoculate people aged 60-65.
Belgium also decided to set age limit for the use of the AstraZeneca vaccine, which is for use by aged 55 and above, according to local media on Wednesday.
A number of countries, as among them Canada, the Netherlands and Germany, have also suspended or limited the use of the AstraZeneca vaccine due to safety concerns.
Various-Coronavirus/AstraZeneca
Dateline : April 7, 2021
Location : Various
Duration : 2'06
FILE: Bristol, UK - 2021 (CGTN - No access Chinese mainland)
1. Various of medical worker preparing for vaccination with AstraZeneca vaccine
2. Various of elderly woman receiving AstraZeneca vaccine
FILE: London, UK - May 2, 2020 (CCTV - No access Chinese mainland)
3. UK national flag
FILE: London, UK - Jan 6, 2021 (CCTV - No access Chinese mainland)
4. "Keep Safe" sign at roadside
FILE: London, UK - Jan 12, 2021 (CCTV - No access Chinese mainland)
5. Various of pedestrians; buildings; traffic
6. Empty street
7. Tower Bridge
FILE: Madrid, Spain - Exact Date Unknown (CCTV - No access Chinese mainland)
8. Spanish national flag
Madrid, Spain - March 24, 2021 (CGTN - No access Chinese mainland)
9. Various of medical workers, residents in COVID-19 vaccination center; residents receiving vaccine
FILE: Madrid, Spain - Oct 3, 2020 (CGTN - No access Chinese mainland)
10. Various of pedestrians, people dining outdoor
FILE: Brussels, Belgium - Exact Date Unknown 2020 (CGTN - No access Chinese mainland)
11. Various of closed restaurants
12. Various of pedestrians; sign of mask wearing mandate
13. Various of medical staff dealing tubes of nucleic acid test at lab
14. Machine lifting tubs
Many countries in Europe have set the limit to age for the use of Oxford-AstraZeneca COVID-19 vaccine following occurrences of blood clot case after the jab.
In the United Kingdom, people aged 18-29 will be offered an alternative to the Oxford-AstraZeneca vaccine amid concerns over its possible link to reported rare cases of blood clots, the British government's vaccination advisory body, the Joint Committee on Vaccination and Immunization (JCVI), said Wednesday.
The announcement by the JCVI follows a review of the Oxford vaccine by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA said the side-effects of the AstraZeneca vaccine were extremely rare and the vaccine's effectiveness is proven, adding that the benefits of taking the vaccine are still very favorable for the vast majority.
However, it conceded the new approach is more finely balanced for younger people because the risk from coronavirus is much lower.
According to the MHRA, Britain has vaccinated more than 20 million people with the AstraZeneca vaccine and up to March 31, 79 cases of rare blood clots were reported, including 51 women and 28 men aged 18-79.
Also, on Wednesday, the European Medicines Agency (EMA) confirmed that the occurrence of blood clots with low blood platelets are strongly associated with the administration of AstraZeneca vaccine but should be still listed as a very rare side-effect.
In its latest assessment, EMA experts told the media that the reported combination of blood clots and low blood platelets is very rare, and the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.
EMA's Pharmacovigilance Risk Assessment Committee made the conclusion after carrying out an in-depth review of the more than 80 cases reported in the European Union (EU) database.
Following the EMA’s assessment, Spain has limited the use of AstraZeneca vaccine on Wednesday. The country announced to ban the use of the very vaccine for people under 60 and only to inoculate people aged 60-65.
Belgium also decided to set age limit for the use of the AstraZeneca vaccine, which is for use by aged 55 and above, according to local media on Wednesday.
A number of countries, as among them Canada, the Netherlands and Germany, have also suspended or limited the use of the AstraZeneca vaccine due to safety concerns.
ID : 8186507
Published : 2021-04-08 10:17
Last Modified : 2021-04-08 20:17:00
Source : China Central Television (CCTV),China Global Television Network (CGTN)
Restrictions : No access Chinese mainland
More
